PRESS RELEASE published on 03/30/2023 at 23:00, 3 years 4 months ago Biophytis: The Combined General Meeting will be held on second call on April 17, 2023
PRESS RELEASE published on 03/27/2023 at 08:00, 3 years 4 months ago Biophytis a présenté Sarconeos (BIO101) comme potentiel candidat médicament dans le traitement du COVID long après hospitalisation, lors du 13ème Congrès annuel International sur la Fragilité et la Sa
PRESS RELEASE published on 03/27/2023 at 08:00, 3 years 4 months ago Biophytis: Biophytis presented Sarconeos (BIO101) as a possible treatment candidate for long COVID after hospitalization during the 13th annual International Conference on Frailty and Sarcopenia Resea
PRESS RELEASE published on 03/17/2023 at 08:00, 3 years 4 months ago Biophytis announces ratio change under its American Depositary Receipt (“ADR”) program
PRESS RELEASE published on 03/17/2023 at 08:00, 3 years 4 months ago Biophytis annonce un changement de ratio pour son programme d'American Depositary Receipt ('ADR')
PRESS RELEASE published on 03/09/2023 at 08:00, 3 years 4 months ago Biophytis To Present Positive Results of Phase 2-3 COVA Study At ERS 2023 21st Lung Science Conference
PRESS RELEASE published on 03/09/2023 at 08:00, 3 years 4 months ago Biophytis présente les résultats positifs de Phase 2-3 COVA à la 21ème Conférence « Lung Science » - ERS 2023
PRESS RELEASE published on 03/02/2023 at 00:00, 3 years 5 months ago Biophytis annonce la signature d’un accord-cadre avec Intsel Chimos, laboratoire pharmaceutique qui exploitera Sarconeos (BIO101) en France pour le traitement des formes sévère de COVID-19
PRESS RELEASE published on 03/02/2023 at 00:00, 3 years 5 months ago Biophytis announces the signature of a master service agreement with Intsel Chimos, a pharmaceutical company that will operate Sarconeos (BIO101) in France for the treatment of severe forms of COVID-1
PRESS RELEASE published on 02/27/2023 at 08:00, 3 years 5 months ago Biophytis: Biophytis démarre le processus règlementaire de demande d’autorisation d’accès précoce en France auprès de la Haute Autorité de Santé (HAS) pour le traitement avec Sarconeos (BIO101) des fo
Published on 08/07/2026 at 23:15, 21 hours 48 minutes ago Faraday Copper Reports Second Quarter 2026 Financial Results
Published on 08/07/2026 at 23:00, 22 hours 3 minutes ago Rio Grande Resources Announces up to $2,500,000 Non-Brokered Private Placement Financing
Published on 08/07/2026 at 22:30, 22 hours 33 minutes ago UraniumX Deploys $3.8 Million to Athabasca Basin Exploration
Published on 08/07/2026 at 22:15, 22 hours 48 minutes ago Noram Lithium Engages 1353656 BC Ltd. for Marketing and Management Consulting Services
Published on 08/08/2026 at 16:25, 4 hours 38 minutes ago Bybit Sues North Korea and Lazarus Group, Secures Preliminary Injunction Freezing Stolen Assets in Landmark Crypto Asset Recovery Effort
Published on 08/07/2026 at 23:21, 21 hours 42 minutes ago EQS-Adhoc: Northern Data Group reports Q2 2026 including the adverse fair value movement on contingent consideration
Published on 08/07/2026 at 19:30, 1 day 1 hour ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 08/07/2026 at 19:15, 1 day 1 hour ago ABO Energy Agrees Sale of Its Polish and Hungarian Subsidiaries
Published on 08/07/2026 at 18:10, 1 day 2 hours ago Stabilus SE: Andreas Jaeger steps down as Chief Financial Officer at his own request
Published on 08/07/2026 at 18:54, 1 day 2 hours ago Covivio - Déclaration des transactions sur actions propres réalisées du 03 août 2026 au 07 août 2026
Published on 08/07/2026 at 18:54, 1 day 2 hours ago Covivio - Information on Treasury shares transactions between August 3rd, 2026, and August 7th, 2026
Published on 08/07/2026 at 18:40, 1 day 2 hours ago Disclosure of transactions in own shares from August 3 to August 7, 2026
Published on 08/07/2026 at 18:40, 1 day 2 hours ago Déclaration hebdomadaire d'opérations effectuées du 3 au 7 août 2026
Published on 08/07/2026 at 18:00, 1 day 3 hours ago LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 juillet 2026
